Featured News
EIX DEADLINE ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Edison International Investors to Secure Counsel Before Important April 21 Deadline in Securities Class Action First Filed by the Firm – EIX
A securities class action lawsuit has been filed against Edison International (EIX) for allegedly making false and misleading statements about its Public Safety Power Shutoffs program, which resulted in heightened fire risk and legal exposure. Investors who purchased EIX securities during the class period are encouraged to join the lawsuit before the April 21, 2025 deadline.
Tejon Ranch Co. Successfully Executing Proven Value-Creation Strategy For Our Shareholders
Tejon Ranch Co. urges shareholders to vote for its director nominees, rejecting a campaign by Bulldog Investors. Tejon highlights its successful long-term development strategy and the lack of relevant experience of Bulldog's nominees.
ATKR DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Atkore Inc. Investors to Secure Counsel Before Important April 23 Deadline in Securities Class Action – ATKR
A class action lawsuit has been filed against Atkore Inc. (NYSE: ATKR) for allegedly making false and misleading statements about its involvement in an anticompetitive price-fixing scheme that artificially inflated the price of PVC pipes. The lawsuit claims that as the scheme was exposed, Atkore's business and operations were negatively impacted, and investors suffered damages.
Portland General Electric declares dividend
Portland General Electric (POR) has declared a quarterly common stock dividend of $0.525 per share, representing a 5% increase on an annualized basis. The company's dividend is evaluated based on capital requirements and financial performance, with a target payout ratio of 60-70% over the long term.
Why Verve Therapeutics Zoomed 40% Higher This Week
Verve Therapeutics' stock price jumped 40% this week after the company published positive initial data from a phase 1b clinical trial of its drug VERVE-102, which targets a genetic disorder that causes high cholesterol levels. Several analysts raised their price targets for the stock, with one even upgrading it to a buy recommendation.
Latest News
SWKS Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Skyworks Solutions, Inc. (SWKS)
A securities fraud class action lawsuit has been filed against Skyworks Solutions, Inc. (SWKS) on behalf of investors who purchased or acquired Skyworks securities between July 30, 2024, and February 5, 2025. The lawsuit alleges that Skyworks made materially false and misleading statements about its business, operations, and prospects.
Why DaVita Stock Got Rocked This Week
DaVita, a healthcare company, suffered a ransomware attack that disrupted its operations. Investors reacted negatively, causing a 10% drop in the stock price, due to the uncertainty around the full impact of the attack.
ROSEN, A LEADING LAW FIRM, Encourages Firsthand Technology Value Fund, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SVVC
A shareholder has filed a class action lawsuit against Firsthand Technology Value Fund, Inc. (SVVC) on behalf of investors who purchased or acquired the company's common stock between January 1, 2021 and November 14, 2023. The lawsuit alleges that the company's managers and/or service providers destroyed over $200 million in shareholder value and inflated the value of the company's remaining investments to hide further losses.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics announced the grant of inducement stock options covering 297,600 shares to 50 new, non-executive employees. The stock options have an exercise price of $3.06 and vest over a three-year period.
Broadcom Stock Just Bounced After One of Its Sharpest Declines in a Decade. Is the Stock a Buy Now?
Broadcom's stock price has bounced back after a sharp decline, but the article suggests that the stock may be overvalued even for a high-quality business. The article discusses Broadcom's growth potential in the semiconductor industry, particularly in the AI market, but cautions that the current valuation may be too high.
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Everus Construction Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ECG
A class action lawsuit has been filed against Everus Construction Group, Inc. (ECG) for making false and/or misleading statements during the class period from October 31, 2024 to February 11, 2025. Investors who purchased ECG stock during this period or held MDU Resources Group, Inc. (MDU) stock and acquired ECG stock in the spinoff may be eligible for compensation.
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages enCore Energy Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EU
A class action lawsuit has been filed against enCore Energy Corp. (EU) for allegedly making false and/or misleading statements during the class period from March 28, 2024 to March 2, 2025. Investors who purchased enCore securities during this period may be entitled to compensation.
Apple Gets Some Relief from President Trump's Tariffs. Could That Turn the Stock Around?
Apple has received a temporary exemption from tariffs on its electronics, providing some relief. However, the exemption is only temporary, and a semiconductor-specific tariff is expected in the near future. Apple's stock has fallen 20% from its highs, and the company faces challenges in growing sales and potentially raising prices to offset tariff effects.
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE
A class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. (CERE) for allegedly making false and/or misleading statements in connection with a secondary stock offering and a merger with AbbVie Inc.
Every Nvidia Investor Should Keep an Eye on This Number
Nvidia's data center revenue, which includes GPUs and other hardware, has become its largest business segment, accounting for over 90% of its total revenue in Q4 FY2025. This growth is driven by the company's dominance in powering the development of artificial intelligence (AI). However, investors should closely monitor any signs of a decline in data center revenue growth, as it could impact Nvidia's valuation and stock performance.